42 results on '"Luppi, G."'
Search Results
2. A37 - Outcome and prognostic factors after resection of liver metastases in patients with colorectal cancer
3. Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer
4. O-019 Distant-relapse analysis of STAR-01, a randomized phase III trial comparing preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer
5. P-149 Integrative analysis of the genomic and transcriptomic landscape identifies novel key genes as a therapeutic target in bile duct cancer
6. Anemia may influence the outcome of patients undergoing neo-adjuvant treatment of rectal cancer
7. Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study
8. 425P Statins increase pathological response in locally advanced rectal cancer (LARC) treated with chemo-radiation (CRT): A multicentric experience
9. 63P Multicentre match-paired analysis of advanced biliary cancer (ABC) long-term survivors: The BILONG study
10. 57P Third-line chemotherapy in advanced biliary cancers (ABC): Pattern of care, treatment outcome and prognostic factors from a multicenter study
11. 1486P The impact of CT-based body composition parameters on survival outcomes in Western patients (pts) with resected gastric and gastroesophageal junction adenocarcinoma (GEA)
12. 1474P Immune-inflammatory indexes and BMI as predictors of outcome and treatment response in advanced gastric cancer receiving ramucirumab-containing second-line
13. 1746P Impact of PD-1/PD-L1 blockade therapy in COVID-19 infected cancer patients (pts) hospitalization: Results of an Italian study in the province of Modena and Reggio Emilia during SARS-CoV-2 outbreak
14. P-292 Locally advanced esophageal cancer: Pattern of care, treatment outcomes and prognostic factors over a 20-year experience at the Modena Cancer Centre
15. SO-12 Multicentre validation of an immune-inflammation-based nomogram to predict survival in western resectable gastroesophageal adenocarcinoma: The NOMOGAST
16. Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC)
17. "MISURA" PROJECT: A RETROSPECTIVE SURVEY ON THE USE OF 5FLUOROURACIL (5FU) IN THE TREATMENT OF COLORECTAL CANCER (CRC) IN 24 ITALIAN CLINICAL CENTRES
18. ADJUVANT CHEMO-RADIOTHERAPY IN RECTAL CANCER (RC)
19. Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC)
20. Intermittent or continuous panitumumab (PAN) plus FOLFIRI for first-line treatment of patients (pts) with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC): A randomized phase II trial (IMPROVE)
21. Outcome and prognostic factors after resection of liver metastases in patients with colorectal cancer
22. The prognostic impact of sidedness across all stages during the last 20 years: the “Modena Cancer Registry” experience
23. BRAF, NRAS and C-KIT mutations segregate distinct clinical and histopathological profiles in patients with melanoma
24. Metformin impact on progression-free survival in diabetic patients with advanced pancreatic neuroendocrine tumors (pNET) receiving everolimus and/or somatostatin analogues. The PRIME-NET (Pancreatic multicentric, Retrospective, Italian MEtformin) study
25. Appendiceal neuroendocrine tumors: a large multicentre Italian series. Preliminary result
26. LBA18_PR - Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC)
27. 609TiP - Intermittent or continuous panitumumab (PAN) plus FOLFIRI for first-line treatment of patients (pts) with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC): A randomized phase II trial (IMPROVE)
28. Everolimus in locally advanced rectal cancer (E-LARC study, Ib): biomarkers evaluation
29. Impact of time to surgery after neoadjuvant chemotherapy in patients with operable breast cancer
30. Multidisciplinary approach for squamous head and neck cancers: a single report institution
31. The role of the activation of mTOR pathway in patients with advanced neuroendocrine tumors treated with everolimus
32. A23 - The prognostic impact of sidedness across all stages during the last 20 years: the “Modena Cancer Registry” experience
33. A Phase Ib Study of Everolimus, 5-Fluorouracil (5-Fu) and Pelvic Radiotherapy (Rt) As Neo-Adjuvant Treatment for Locally Advanced Rectal Cancer (Larc)
34. Real-World Study on Oxaliplatin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms : Clinical Outcomes and Preliminary Correlation with Biological Factors
35. M07 - BRAF, NRAS and C-KIT mutations segregate distinct clinical and histopathological profiles in patients with melanoma
36. B22 - Appendiceal neuroendocrine tumors: a large multicentre Italian series. Preliminary result
37. B06 - Metformin impact on progression-free survival in diabetic patients with advanced pancreatic neuroendocrine tumors (pNET) receiving everolimus and/or somatostatin analogues. The PRIME-NET (Pancreatic multicentric, Retrospective, Italian MEtformin) study
38. Everolimus (EVE) Exposure in Patients (PTS) with Previously Treated advanced Gastric Cancer (AGC)
39. 1150P - Real-World Study on Oxaliplatin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms : Clinical Outcomes and Preliminary Correlation with Biological Factors
40. 591P - A Phase Ib Study of Everolimus, 5-Fluorouracil (5-Fu) and Pelvic Radiotherapy (Rt) As Neo-Adjuvant Treatment for Locally Advanced Rectal Cancer (Larc)
41. Multifocal leukoencephalopathy associated with 5-fluorouracil and levamisole adjuvant therapy for colon cancer. A report of two cases and review of the literature
42. 318P Pattern of expression, transcriptional states and clinical implications of tumour-infiltrating lymphocytes (TILs) in curatively-treated cholangiocarcinoma (CCA) patients (pts): The TILBIL study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.